NeonMind is exploring using psilocybin as an innovative approach to weight loss. Through a preclinical trial, the company is investigating if psilocybin can help to tackle obesity using their molecule NEO-001 in tandem with psychotherapy.
Additionally, NeonMind plans to expand into the clinical market. The company hopes to launch its first clinic offering psychedelic-assisted therapies by the end of 2021.
NeonMind
In October 2021, Neonmind announced a brokered private placement of up to 2,000 units of the company at a price of CAD 1,000 per unit for gross proceeds of up to C$2,000,000.
News
- NeonMind Advances Strategy For Specialty Clinic Launch (Yahoo Finance, September 2021)
Activities
B2B
B2C
Biotech
Clinic
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal Subjects (Psychedelic Finance, 23 March 2022)NeonMind Files Provisional Patent Application For Psilocybin Induced Weight Loss (Benzinga, 22 March 2022)